OIF Patient-led Listening Session at the U.S. Food and Drug Administration (FDA)

09/17/2019

Objective of session
The objectives of the session were to discuss with the U.S. Food and Drug Administration (FDA) the impactful symptoms of osteogenesis imperfecta (OI), the experience of living with OI, as well as the impacts that current treatments have on daily life. Lastly, the group wanted to discuss the importance of including endpoints other than fracture in future research. Continue reading “OIF Patient-led Listening Session at the U.S. Food and Drug Administration (FDA)”